LOH by regions

• 22q13 LOH
  13 February 2006

  Tumors
  capillary hemangioblasoma (#15343513#)
  References
  Beckner ME, Sasatomi E, Swalsky PA, Hamilton RL, Pollack IF, Finkelstein SD. Loss of heterozygosity reveals non-VHL allelic loss in hemangioblastomas at 22q13. Hum Pathol. 2004 Sep;35(9):1105-11. PMID: #15343513#

• 18q21 LOH
  5 January 2006

  Tumors (Exemples)
  colorectal adenocarcinoma
  clear cell renal cell carcinoma (19%)
  pulmonary carcinomas (lung cancer)
  Target region
  18q21.3 (18q21 LOH) candidate gene: DCC, SMAD4
  Candidate genes
  DCC at 18q21
  SMAD4 at 18q21
  See also
  loss of heterozygosity (LOH)
  inactivation of tumor suppressor genes

• 18q LOH
  5 January 2006

  Tumors (Exemples)
  colorectal adenocarcinoma
  clear cell renal cell carcinoma (19%)
  pulmonary carcinomas (lung cancer)
  Target region
  18q21.3 (18q21 LOH) candidate gene: DCC, SMAD4
  Candidate genes
  DCC at 18q21
  SMAD4 at 18q21
  See also
  loss of heterozygosity (LOH)
  inactivation of tumor suppressor genes

• 1q LOH
  7 December 2005

  Regions
  1q21-23 LOH
  1q25 LOH
  Tumors
  gastrinoma
  insulinoma (88%) (#15900598#)
  esophageal squamous cell carcinoma (75%) (#15766597#)

• 19p13 LOH
  5 December 2005

  Target gene: STK11 at 19p13.3

• 9q22 LOH
  5 December 2005

  Target gene: PTCH

• 4p16 LOH
  31 October 2005

  Tumors
  colorectal adenocarcinoma (40-49%) (#11230704#)
  cervical squamous cell carcinoma (25%-92%)
  bladder urothelial carcinoma (22%) (bladder cancer) (4p16.3) (#7970702#)
  bronchial squamous cell carcinoma 4p16 had been shown to be lost in the transition from carcinoma in situ to invasive tumor.
  Candidates genes
  FGFR3
  CRMP1 is a lung cancer metastasis-suppressing gene.
  PPP2R2C gene coding for a regulatory subunit of the PP2 complex known to suppress tumorigenesis, (...)

• 9p13 LOH
  31 October 2005

  Tumors pulmonary squamous cell carcinoma 3% #16213358#

• 17p13 LOH
  31 October 2005

  Inactivated genes
  TP53
  Tumors Tumors % hepatocellular carcinoma 64%

• metastasis allelotyping
  31 October 2005

  Histopathologic techniques are insufficient for distinguishing primary squamous cell carcinoma (SCC) from metastatic SCC, which is clinically important.
  When multiple tumors are present, determining metastatic versus synchronous primary tumors is necessary for appropriate treatment. Identification can be achieved using allelotyping for loss of heterozygosity.
  Open references
  Metastatic squamous cell carcinoma of the anus to the lung confirmed with allelotyping. Roth R, Moffatt-Bruce S, (...)

0 | 10 | 20 | 30 | 40 | 50 | 60